March 14, 2018
C3i Solutions, a business process outsourcer specializing in global, high-touch consumer, patient and end user engagement, today announced it has been named by Gartner, Inc. as a Representative Vendor in the Gartner Market Guide for Customer Management BPO Services (1) and recognized as a Niche Player in the Magic Quadrant for Managed Workplace Services, North America (2).
This is the first time C3i Solutions has been placed in Gartner’s Market Guide for Customer Management BPO Service Providers which “reviews key service providers managing marketing, sales and customer service processes.”
“Over the past 35 years, C3i Solutions has been dedicated to building lasting relationships with consumers on behalf of more than 700 brands in the food and beverage, health & beauty and consumer packaged goods industries. We are proud to be acknowledged for the first time in this Market Guide and believe this distinction confirms our client focus and commitment to industry leading customer satisfaction,” says Frank Pettinato, senior vice president, multi-channel consumer engagement at C3i Solutions.
“Increasingly, organizations recognize that next-generation managed workplace services (MWS) are crucial to increase staff engagement, drive productivity and enable digital benefits,” the report, Magic Quadrant for Managed Workplace Services, North America states. For the second year in a row, C3i Solutions is among the 20 vendors that Gartner recognized in the North American market according to their ability to execute and completeness of vision.
“In an ever-changing climate, we are committed to delivering a customer-centric approach that gives our clients a unique advantage to improve the end user experience, while positively managing costs. We feel that being identified again in the Magic Quadrant for Managed Workplace Services, North America demonstrates that we continue to be a valued partner of choice for our pharmaceutical and life sciences clients,” says Robert Piwko, executive vice president, sales and account management, C3i Solutions. “In our view, this dedication is not limited to our operations in North America — it applies to our services offered to organizations of all sizes around the globe.”
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise
technology users to select only those vendors with the highest ratings or other designation. Gartner research
publications consist of the opinions of Gartner’s research organization and should not be construed as statements of
fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of
merchantability or fitness for a particular purpose.
About C3i Solutions:
C3i Solutions (formed with the merger of Telerx and C3i Healthcare Connections) is a business process outsourcer
specializing in global, high-touch consumer, patient and end user engagement. Our network of 12 global contact centers provides unparalleled, 24/7, multi-lingual support to customers in over 175 countries. For the past 35 years, our unique, multi-channel approach and experience in highly regulated industries have made us the partner-of-choice for some of the world’s most trusted brands. With a strategic focus on innovation, we excel at protecting our clients’ brands, while maximizing productivity and cost efficiency. C3i Solutions is part of Healthcare Services & Solutions, LLC, a whollyowned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada). For more information, visit lifesciencescare.hcltech.com or connect with us on LinkedIn, Twitter@C3iLifeSci, Twitter@C3iCustCare, and Facebook.
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United
States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new
information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2017 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
To find the press release on Business Wire, click here.
Jackie Hoover, 917-599-7279
As an industry leader in business process outsourcing, HCL Technologies delivers global, multi-channel engagement solutions. The Experience Matters. Let us show you why.Contact Us